The performance of different antibody combinations in distinguishing NPC (n = 46) from non‐NPC participants with an elevated risk as determined by the combination of EBNA1/IgA and VCA/IgA (n = 263). This evidence concerns the gene CD79A and nasopharyngeal carcinoma.